Navigation Links
Switching immunosuppressants reduces cancer risk in kidney
Date:10/31/2009

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

"In spite of the life-saving nature of organ transplantation, the need for transplant recipients to continue treatment with drugs that suppress the immune system to prevent rejection of the organ is associated with a number of side effects, one of which is the development of cancer," said lead researcher Graeme Russ, MD (The Queen Elizabeth Hospital, Australia). "So the search for an immunosuppressive drug which prevents rejection effectively but is associated with lower rates of cancer will be of significant advantage to transplant recipients."

The study included 86 kidney transplant patients who previously had skin cancer (other than melanoma)placing them at particularly high risk of new skin cancers. In Australia, skin cancer is the most common type of cancer occurring post-transplant.

One group of patients remained on standard immunosuppressant drug treatment. The other group was switched to treatment with sirolimusone of a newer class of immunosuppressants called mTOR inhibitors. "Previous studies have suggested that mTOR inhibitors are associated with less cancer than other commonly used agents," according to Russ.

Patients switched to sirolimus had a significantly lower rate of new skin cancers. Overall, new skin cancers developed in 56 percent of patients in the sirolimus group, compared to 81 percent of those who remained on the standard immunosuppressant. Most of the difference reflected a lower rate of one type of cancer, called squamous cell carcinoma.

Nearly half of patients stopped taking sirolimus because of side effects. "In spite of this large dropout rate there was a significantly lower rate of skin cancer development in the sirolimus group," said Russ. Switching to sirolimus did not increase the risk of rejection of the transplanted kidney.

Switching immunosuppressants may offer a new option to reduce the high risk of skin cancer for transplant recipients, the researchers believe. Russ added, "This is the first randomized controlled trial to address whether patients treated with mTOR inhibitors after renal transplantation have less skin cancer."


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-558-8423
American Society of Nephrology
Source:Eurekalert  

Related medicine news :

1. Switching early breast cancer patients to exemestane improves long-term survival
2. AUDIO from Medialink and Forest Laboratories: Dangers of Switching Medications
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit
5. Senator Specter: Switching Parties or Coming Home?
6. Patients Urged to be Aware of Prescription Switching
7. Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans
8. Walgreens Pays $35 Million, Settles Pharmacist-Whistleblower Qui Tam Drug Switching Allegations
9. Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Investigation
10. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
11. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Switching immunosuppressants reduces cancer risk in kidney
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or ... used in such facilities are specially designed to accommodate patients with a wide range ... An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that ... be used to complete regulatory submissions and fund final engineering and initial production ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... company of over 2,000 employees and a leader in environmental and life science ... their position as the top American owned and operated environmental testing firm in ... ... ... , enhances Pace Analytical,s capability as an innovative full service provider in ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology: